Voriconazole use for endemic fungal infections.
In a retrospective review of 24 patients with histoplasmosis, blastomycosis, or coccidioidomycosis treated with voriconazole (most for salvage therapy), the outcome was favorable (improved or stable) for 22 (95.8%) within 2 months of starting voriconazole and for 20 (83.3%) at the last follow-up. Prospective studies are required to determine its role in the treatment of endemic mycoses.
Freifeld
Alison
A
University of Nebraska Medical Center, Omaha, Nebraska, USA. afreifeld@unmc.edu
Proia
Laurie
L
Andes
David
D
Baddour
Larry M
LM
Blair
Janis
J
Spellberg
Brad
B
Arnold
Sandra
S
Lentnek
Arnold
A
Wheat
L Joseph
LJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D001759:Blastomycosis / Q000188:drug therapy*; D003047:Coccidioidomycosis / Q000188:drug therapy*; D005260:Female; D006660:Histoplasmosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D014230:Triazoles / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole